AHS (American Headache Society) June 3-6 2021
Botox published abstract
Real-World Safety and Efficacy of 156-195U OnabotulinumtoxinA in Participants with Chronic Migraine: Results from the REPOSE Study
Consecutive Headache-Free Days with OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: A Pooled PREEMPT Analysis
Real-World Evidence for Control of Patients with Chronic Migraine Who Received Calcitonin Gene-Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment
IL-BTX-2150041